x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2016 > 3rd ESO Lung Cancer Observatory: innovation and care in the next 12 months
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

3rd ESO Lung Cancer Observatory: innovation and care in the next 12 months

Not eligible for ESCO credits

15.04.2016

Geneva, Switzerland

COURSES AND SEMINARS

Lung cancer

Description

Chairs: M.S. Aapro, CH - E. Felip, ES



The European School of Oncology is pleased to announce the 3rd edition of "ESO Lung Cancer Observatory: innovation and care in the next 12 months", which will be held during the ELCC 2016 European Lung Cancer Conference on April 15 in Geneva, chaired by Dr. M.S Aapro and Dr. E. Felip, ES. The scope of the session is to provide the participants with a take home message on what they can expect to happen in the prostate cancer field in the next 12 months.


The Observatory will be held during the



 

 

General information

ESO SECRETARIAT
Daniela Mengato
European School of Oncology
Via Turati 29
20121, Milan, Italy
dmengato@eso.net



VENUE
Palexpo
30 Route François-Peyrot
1218 Le Grand-Saconnex
Geneva
Switzerland



ATTENDANCE

Attendance is granted to all participants registered to the ELCC 2016 European Lung Cancer Conference.


CONCLUSION
The conclusion of the Observatory will be made available on the ESO website.

 

 

.

 

Faculty list


PANELLISTS

M.S. Aapro, Clinique de Genolier, CH
E. Felip, Vall d’Hebron University Hospital, Barcelona, ES
F. Johansson, Swedish Lung Cancer Association "Stodet", Stockholm, SE
K. Kerr, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
F. Mornex, Centre Hospitalier Lyon Sud, FR
U. Pastorino, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, IT





Programme


PROGRAMME
16:45 - 18:15 - Palexpo, Room W

Screening and surgery advances
U. Pastorino IT
Therapeutic management of unresectable stage III NSCLC: an update
F. Mornex, FR
Anti-PD1 and anti-PDL1 strategies in NSCLC: Their potential role in NSCLC treatment
E. Felip, ES
Predictive markers in NSCLC
K. Kerr, UK
Long-term lung cancer survivors: Patient needs
F. Johansson, SE